

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 16/22, A61K 39/395, G01N 33/577, A61P 35/00, 13/12, 27/02, 37/00, 11/06		A1	(11) International Publication Number: WO 00/66631
			(43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/GB00/01679			Brampton Road, Cambridge, Cambridgeshire CB1 3HL (GB). TEMPEST, Philip, Ronald [GB/GB]; 43 High Street, West Wrating, Cambridgeshire CB1 5LU (GB).
(22) International Filing Date: 2 May 2000 (02.05.00)			
(30) Priority Data: 60/131,983	30 April 1999 (30.04.99)	US	
(71) Applicant (<i>for all designated States except US</i>): CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED [GB/GB]; The Science Park, Melbourn, Royston, Cambridgeshire SG8 6JJ (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): THOMPSON, Julia, Elizabeth [GB/GB]; Seaby's Cottage, 6 High Street, Whittleford, Cambridgeshire CB2 4LT (GB). LENNARD, Simon, Nicholas [GB/GB]; 58 Horesham Close, Hanchett Village, Haverhill, Suffolk CB9 7HN (GB). WILTON, Alison, Jane [GB/GB]; Fitzwilliam Cottage, 46 Huntingdon Road, Cambridge CB3 0HN (GB). BRADDOCK, Peta, Sally, Helena [GB/GB]; 6 Woodlands, St. Neots, Huntingdon, Cambridgeshire PE19 1UE (GB). DU FOU, Sarah, Leila [GB/GB]; 76 Ickleford Road, Hitchin, Hertfordshire SG5 1TL (GB). MCCAFFERTY, John, Gerald [GB/GB]; Church Farm Cottage, Sawston Road, Brabraham, Cambridgeshire CB2 4AP (GB). CONROY, Louise, Anne [GB/GB]; 35			
(54) Title: SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ1			
(57) Abstract			
<p>The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGFβ1 and are useful in treating conditions associated with excess TGFβ1 activity, such as fibrosis, immune responses and tumour progression.</p>			

(54) Title: **SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGF β 1**

(57) Abstract

The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF β 1 and are useful in treating conditions associated with excess TGF β 1 activity, such as fibrosis, immune responses and tumour progression.

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.